Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities from novel lymphoma therapies.

Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care

FLAURA2 data show osimertinib plus chemotherapy significantly improves overall survival vs osimertinib alone in frontline EGFR+ advanced NSCLC.

Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

Lutetium Li 177 dotatate was linked with partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors, per real-world data.

Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

Benjamin Besse, MD, PhD, shares AE management strategies with amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.

Safety Management With Amivantamab Plus Lazertinib in NSCLC

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Events

Subscribe

Partners

Nicole Ferreira, MSN, RN, NPD-BC, BMTCN, OCN, serves as a nursing professional development specialist at Vanderbilt University Medical Center in Nashville, Tennessee.

Articles

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

How best can senior staff and leadership support nurses new to the field of oncology?

Transforming Oncology Nurse Education Through Fellowship Programs

Lorenzo Falchi, MD, a lymphoma specialist at Memorial Sloan Kettering Cancer Center in New York, New York.

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Michelle Kirschner, RN, MSN, ACNP, APRN-BC, is a nurse practitioner and director of program development at the Cancer Survivorship and Supportive Care Professionals Network.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.

Precision Supportive Care Centers Patient Preference in Oncology

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

View

The Advent of Oral Oncolytics and Patient Access

Multidisciplinary Approach to Managing Oral Oncolytics

Roles of the Oncologist Versus Pharmacist

The Efficacy and Safety of CDK4/6 Inhibitors

Practical Challenges in Switching to CDK4/6 Inhibitors

Medically Integrated Dispensing Service Best Practices

Oral Oncolytics and Patient Adherence

Medically Integrated Pharmacy Teams Spur Innovations

CDK4/6 Inhibitors in Metastatic Breast Cancer

Considerations for Treating Patients with CDK4/6 Inhibitors

Multidisciplinary Care in Breast Cancer

Best Practices for Managing Patients on CDK4/6 Inhibitors

Educating Patients and Staff on Using CDK4/6 Inhibitors

Improving Care for Patients With Metastatic Breast Cancer

Metastatic Breast Cancer: CDK4/6 Inhibitors

Benefits and Challenges of CDK4/6 Inhibitors

Patients' Perspectives on CDK4/6 Inhibitors

Multidisciplinary Approach: Managing CDK4/6 Inhibitors

Dispensing of CDK4/6 Inhibitors

Patient Management of CDK4/6 Inhibitors

Adherence With CDK 4/6 Inhibitors

Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer

Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer

Newsletter

Latest Conference Coverage